Cite

HARVARD Citation

    Blauvelt, A. et al. (2018). Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. British journal of dermatology. pp. 623-631. [Online]. 
  
Back to record